It has been postulated that the patient with atopic dermatitis has defective beta adrenergic receptor function. However, a more generalized defect is suggested by the observation that cyclic AMP generation is diminished in these patients following stimulation with both isoproterenol and PGE1• To determine the nature of this abnormality, we measured beta adrenergic receptor binding directly on polymorphonuclear leukocyte membranes using the radiolabeled beta adrenergic antagonist (-) ['IH] dihydroalprenolol (DHA). DHA binding was studied in 6 mild and 9 moderate-to-severe atopic dermatitis patients, and 8 normal controls using a subsaturating concentration of DHA (0.5 nM) to estimate receptor affinity and a saturating concentration of DHA (30 mM) to determine the total number of receptors per cell.
It has been postulated that the patient with atopic dermatitis has defective beta adrenergic receptor function. However, a more generalized defect is suggested by the observation that cyclic AMP generation is diminished in these patients following stimulation with both isoproterenol and PGE1• To determine the nature of this abnormality, we measured beta adrenergic receptor binding directly on polymorphonuclear leukocyte membranes using the radiolabeled beta adrenergic antagonist (-) ['IH] dihydroalprenolol (DHA). DHA binding was studied in 6 mild and 9 moderate-to-severe atopic dermatitis patients, and 8 normal controls using a subsaturating concentration of DHA (0.5 nM) to estimate receptor affinity and a saturating concentration of DHA (30 mM) to determine the total number of receptors per cell.
No significant differences (p > .05) were found in the total number of receptors per PMN between the control population (805 ± 95) and the mild atopic dermatitis patients (745 ± 91) or the moderate to severe group (621 ± 79). In addition, no significant differences in receptor affinity were found among any of the 3 study groups. These findings suggest that beta receptor binding in atopic dermatitis is normal. Reduced cyclic AMP generation in atopic dermatitis PMN leukocytes would appear to be due to a defect distal to the beta adrenergic receptor itself.
Szentivanyi [1] has postulated that atopic disease is characterized by a blockade of the beta adrenergic receptor resulting in an imbalance with increased alpha adrenergic and cholinergic receptor function. Clinical and laboratory evidence suggest that an imbalance of the autonomic nervous system exists in atopic dermatitis· and that this phenomenon may be important in the pathogenesis of the disease [2] . Recently, impaired beta adrenergic function in peripheral blood leukocytes of patients with active atopic dermatitis has been reported [3, 4] . Busse and Lee · [3] reported decr eased cyclic adenosine 3,5 monophosphate (cyclic AMP ) responses to isoproterenol in granulocytes and lymphocytes from eczema patients, while Parker, Kennedy, and Eisen [4] showed a decreased response to both isoproterenol and prostaglandin (PG) E" in leukocytes and purified lymphocytes in patient with severe, but not mild atopic dermatitis. These studies suggest that if defective generation of cyclic AMP truly exists in atopic disease, the defect may be distal to the beta adrenergic receptor since a decreased response was seen following stimulation with PGE" as well as isoproterenoL
In order to more clearly identify the abnormality in the pathway to cyclic AMP generation, one must assess the frrst step in the sequence, that of hormone binding to the beta [5] . PMN may be more suitable than lymphocytes for clinical studies of beta adrenergic receptors, because PMN appear to be a more homogeneous population than are lymphocytes [6] [7] [8] . In this study we report our findings of beta adrenergic receptor binding in mild and moderate to severe atopic dermatitis patients compared to a healthy control group.
MATERIALS AND METHODS

Subjects
A total of 15 patients with atopic dermatitis and 8 normal controls were studied. The diagnosis of atopic dermatitis was based on welldefined clinical and historical features as previously described [2] . Extent (E) and severity (S) of disease were graded on a scale of 1-5 and the product of t he 2 grades (E X S) was the overall indicator of clinical involvement [9) . Thus, a score of 25 would indicate maximally severe ge neralized erythroderma. Patients with E X S scores of 10 or under were co nsidered to have mild atopic dermatitis while those wit h scores greater t han 10 were defined as having moderate to severe atopic dermatitis. S ubj ects were divided into three categories as follows.
Group I-control population: There were 8 control subj ects who had no ev idence of atopic dermatit is or other atopic diseases. These subj ects included 5 males and 3 females with a mean age of 36.9 yr for t he group.
Group II-mild atopic derm.a~itis (clinical score :510): This group consisted of 6 patients, 2 males and 4 females with a mean age of 31.8 yr.
Group Ill-moderate-to-severe atopic dermatitis (clinical score > 10): There were 9 patients in this group, 3 males and 6 females, with a mean age of 34.1 yr.
Selective Criteria
The subj ects in all 3 groups were carefully screened to exclude individuals with active viral infection, those receiving adrenocorticosteroids, cardiac glycosides, antihypertensive or other sympathomimetic-containing medication.
Preparation of Polym.orphonuclear (PMN) Particulates
Sixty ml of heparinized blood was obtained fro m each subj ect in t he study. Blood was centrifuged on Ficoll-Hypaque density gradient according to t he method of Boyum [10] . The pellets conta ining erythrocytes and granulocytes were diluted 1:2 with phosphate buffered saline (PBS) and t hen mixed with an equa l volume of 3% (wt/vol) high molecular weight Dextran (1'250 Pharmacia Fine Chemicals, Piscataway, N ew Jersey) in PBS.
The erythrocytes were a llowed to settle for 25 min at room te mperature, and t he Dextran separation procedure was repeated since this second separation increases the PMN yield. The supernatant fraction was then exposed to 0.2% NaCI for 20 seconds in order to lyse contaminating erythrocytes; 1.6% N aCI was used to restore isotonicity, and the cells were centr ifuged at 350 xg for 10 min. The cellular pellet was resuspended in a few ml of PBS and the number of cells was counted. PMN were 90 ± 3.5% (mean ± SD) with the remainder of t he cells less t han 5% lymphocytes, less than 5% eosinophils, less than 1 % basophils a nd less than 1% monocytes. Less t han 1 platelet was found for every nucleated cell counted. The cellular suspension was made hypotonic with 0.2% NaC l for 30 to 40 min at 4°C, a nd t hen centrifuged at 450 xg for 10 min. The pellet was resuspended in incubation buffer [50 mM Tris H CL (pH 8.1 at 4°C), 10 mM MgCb] at a density equivalent to ' 10 8 cells/ml. The suspension was subjected to freeze thawing and then
Beta·Adrenerg ic R eceptor Binding Assay
In a previous study [5] , we found that the dissocia tion constant (KD) for DHA binding to PMN particulates was 1 to 5 nM and, thus, satuI'ation of the binding sites occurred at 10 to 30 nM DHA. In the present study we used two DHA concentrations, 0.5 nM and 30 nM for a ll s ubjec ts. Because of the yield of PMN particulate protein it was impossible to study DHA binding at more than 2 DHA concentrations. W e chose 0.5 nM as a sUbsaturating conce ntration and 30 nM as a concentration that wou ld refl ect the total number of DHA binding s ites. DHA (New England Nuclear) specific activity was 49 Ci/mmol.
Binding assays contained in the total volume of incubation buffer of 0.15 ml: DHA, PMN membranes obtained from 0.75 x 10 7 cells (which corresponds to 440 f.Lg protein) , 1 mM ascorbic acid, 0.3 mM catechol, a nd 0.1 mM phentolamine. Ascorbic acid is included to block oxidation of catecholamines, and catechol and phentolamine to inhibit nonspecific binding [11 ,12] . These agents did not affect specific binding. Samples were incubated at 37°C for 15 min. Incubations were te rmin ated by rapidly diluting samples with 2 ml of ice-cold incubation buffer and t hen immediately fLItering the mixture through a glass fLI ter (Gelman A/ E). The fLIters were presoaked in incubation buffer containing 0.1 mM (±)-propranolol to block nonspecific binding of radioacti vity to the fll ters. The fllters were rapidly (10 seconds) washed with 15 m l of ice-cold incubation buffer and the radioactivity of the dried filters was determined in a liquid scin tillation system ( 'H) efficiency = 45% ). Specific binding represents the total amount of radioactive DHA bound minus the amoun t bound in the presence of 1 p,M (±)-propranolol and was greater than 80% at 0.5 nM and abou t 50% at 30 nM of the total aIDount bound. All data shown in this paper are specific binding. Specific binding was linear with protein at the concentration used in t h ese experim ents. All samples were run as duplicates and these differed from each other by less than 15%. Protein was measured by the method of Lowry, Rosebrough, and Farr [13] using bovine serum albumin standards.
Analy .• is 0,. Bindin.g Data
The quanti ty of DHA binding in fmol/mg protein was determined. S in ce J mg of our p31'ticulate preparation is derived from 1. Each group was co mp31'ed with the others using a nonpaired Student's test analysis for significant differences in binding.
RESULTS
Although the ratio of males to females was slightly different in Group I (5:3) compared to Groups II and III (2:4 and 3:6 respectively ) we have previously s hown no difference in DHA binding between males and fe males (14] . In a ddition, the groups Group II) and those with moderate-to-severe disease (Group III) both at the low DHA concentration (0.5 nM) and at th e saturation DHA concentration (30 nM) in the Table. Statistical analysis revealed no significant difference (p >.05) between the control population and either atopic dermatitis group. This was true at 0.5 nM when one compares Group I at 9.7 ± 1.2 fmol/mg protein (mean ± SEM) with Group II at 9.5 ± 1.7 or Group III with 9.2 ± 0.9, and at the 30 nM DHA concent ration where t h e control group bound 25.4 ± 3.0 fmol/mg protein compared to 23.5 ± 3.0 a nd 19.6 ± 2.5 for t h e mild and moderate-to-severe atopic d ermatitis groups respectively. The total number of receptors was calculated for each group. Group I PMN had 805 ± 95 beta a drenergic r ecep tors per cell compa red to 745 ± 91 a nd 621 ± 79 PMN receptors for Group II a nd III. Again, no statistical difference (p >.05) was found between any of t he group comparisons. Finally, if one uses the percen tage of the total binding at 0.5 nM DHA as an indication of recep tor a ffinity, no significant differe nces are found between groups.
DISCUSSION
In t his report we have found that t h e PMN beta adre nergic recep tor in atopic dermatitis cannot be distinguished statistically from a normal control population regardless of the disease severity. However, since DHA dose r esponse curves were not performed on atopic d ermatit is patien ts because of t h e blood requi.re m en t we h ave not ruled out the possibility of a bnormal DHA binding kinetics in this populat ion. Although this question cannot be presently resolved from this study, we feel our data certainly suggest that the total number of receptors and the estimate of receptor affinity in atopic dermatitis ar e bot h norm al. Patient 3 in Group III has low binding, but he too falls within 2 standard deviations of t h e mean DHA binding found in our laboratory (14) . Although t h e number of subj ects is small , t h ese data ar e very similar to t hose we have r ecently reported in a larger number of patients with bronchial asthma [14, 15] ' Asthmatics have normal binding regardless of t h e severity of t h eir illness unless t h ey are receiving adrenergic drug therapy. Patients with severe atopic dermatitis a ppear to h ave normal binding too, although Parker, Kennedy, and Eisen [4] clearly s howed significantly decreased cyclic AMP responses to both isoproterenol and PGE, in leukocytes from patients with severe but not mild disease. Although these data a ppear to be in conflict a t first, t hey m ay be in fact co nsistent with a d efect in the coupling of the me mbra ne-hormone receptor wit h t h e enzym e adenylate cyclase rat h er t han an ab normality of t h e recep tor itself. This would account for the decreased cyclic AMP response not only to isoproterenol, but PGE] as well. In addition, in bronchial asthma an analogous situation may exist explaining the diminished granulocytes cyclic AMP responsiveness to both histamine [16] and isoproterenol [17] . Atopic dermatitis would appear to provide an excellent model for study of the proposed abnormality of the beta adrenergic system since, unlike asthma, systemic drugs are seldom necessary and abnormalities in leukocyte function including the granulocyte have been identified [18] . Measurement of beta receptor binding and adenylate cyclase activity on the same membrane preparation in a larger number of patients should help elucidate the nature of the diminished cyclic AMP responsiveness. Hopefully these studies will improve our understanding of the pathogenesis of atopic dermatitis as well as other atopic diseases.
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